News
Feed
Events
Feed
News
+ Events
Feed

SphingoTec GmbH

Aktuelle News

15 November 2022

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)

26 August 2022

10:00 Corporate

SphingoTec GmbH

Corporate

Abteilungsübergreifende Testung des Nierenbiomarkers penKid in der Routineversorgung des Universitätsklinikums Heidelberg und dem Nierenzentrum Heidelberg

8 August 2022

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

Medical thought leaders in critical care aim to advance precision medicine using biomarker-based approaches

1 August 2022

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

Endothelial function biomarker bioactive Adrenomedullin (bio-ADM) enables triage of sepsis patients in the emergency department

30 Juni 2022

13:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec appoints Jörg Menten as CEO to accelerate commercialization and global growth

11 April 2022

10:00 Corporate

SphingoTec GmbH

Corporate

Biomarker-gesteuerte Studie unter Leitung des Universitätsklinikums Hamburg-Eppendorf (UKE) eröffnet neue Wege für personalisierte Medizin bei COVID-19

24 März 2022

10:30 Corporate EN

SphingoTec GmbH

Corporate
EN

The Biomarkers bio-ADM and DPP3 Complement Post-Cardiac Surgery Diagnostics to Early Detect Organ Failure

17 März 2022

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec and Rivaara Labs Close Exclusive Distribution Agreement for Point of Care Diagnostics in India

15 März 2022

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

Proenkephalin (penKid) sheds light on the diagnostic blind spots in assessing acute kidney injury in children

29 November 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec Appoints Jörg Menten to Leadership Team as Chief Commercial Officer to Drive New Business Growth

9 September 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec’s innovative biomarkers to enable personalized medicine in septic organ failure

31 August 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

New data on innovative biomarkers used to guide the clinical management of septic patients

23 August 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec Appoints Dr. Gerald Möller as Chairman of the Advisory Board

10 Juni 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec Expands Management Team and Appoints new CFO

20 Mai 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec Accelerates Growth with Direct Sales

4 Mai 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

Endothelial Function Biomarker bio-ADM to Support Risk Stratification and Clinical Management of COVID-19 Patients

23 März 2021

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec GmbH: New diagnostic tool for the management of patients with sepsis: Dipeptidyl Peptidase 3 (DPP3)

18 Februar 2021

10:00 Media EN

SphingoTec GmbH

Media
EN

Two distinct pathways leading to the development of septic shock pave the way for personalized medicine in sepsis

16 Dezember 2020

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

Proenkephalin (penKid(R)) included in the ADQI consensus statements publication as functional kidney biomarker for the management of AKI patients

10 Dezember 2020

10:00 Press Release

SphingoTec GmbH

Press Release

Uniklinik RWTH Aachen implementiert als erste Klinik SphingoTec’s innovative Biomarker in der klinischen Routine mit dem Ziel die intensivmedizinische Diagnostik zu präzisieren

29 September 2020

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec GmbH: SphingoTec, BHR Pharmaceuticals ink agreement for distribution of SphingoTec’s acute care portfolio in the UK and Ireland

27 August 2020

10:00 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec’s kidney function biomarker penKid(R) accurately detects acute kidney injury in infants

6 August 2020

13:13 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec to Present at the Solebury Trout’s Summer Private Company Showcase

31 Juli 2020

12:30 Corporate EN

SphingoTec GmbH

Corporate
EN

SphingoTec to Present at the LifeSci Partners’ Summer Symposium

22 Juli 2020

10:00 Press Release EN

SphingoTec GmbH

Press Release
EN

SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

18 Juni 2020

10:00 Press Release EN

SphingoTec GmbH

Press Release
EN

Sphingotec’s critical care biomarkers early diagnose risk of loss of endothelial, kidney and heart function in severely ill COVID-19 patients

14 Mai 2020

10:00 Press Release EN

SphingoTec GmbH

Press Release
EN

The cardiac depressant factor DPP3 is predicting organ failure in burn patients

Anstehende Events

Keine Events gefunden